Skip to main content

Table 1 Patient characteristics

From: Analysis of using high-precision radiotherapy in the treatment of liver metastases regarding toxicity and survival

Characteristics Values
Number of patients (n) 115
Number of LM 150
Gender (n)
 Male 59 (51.3%)
 Female 56 (48.7%)
Age at SBRT (median, range) [years] 66.1 (34.7–86.1)
Primary entities
 Rectum 16 (13.9%)
 Colon 38 (33.0%)
  Colon ascendens 4 (10.5%)
  Colon transversum 1 (2.6%)
  Colon descendens 2 (5.3%)
  Coecum 3 (7.9%)
  Left/right flexure 3 (7.9%)
  Sigma 16 (42.1%)
  Unknown 9 (23.7%)
 Esophagus/AEG/stomach 12 (10.4%)
 Mamma Ca 20 (17.4%)
 NSCLC 5 (4.3%)
 Pancreas 4 (3.5%)
 Ovary 4 (3.5%)
 Others 16 (13.9%)
Symptoms
 Present 8 (7.0%)
 Absent 107 (93.0%)
KPS
 100% 6 (4.0%)
 90% 83 (55.3%)
 80% 46 (30.7%)
  ≤ 70% 15 (10.0%)
Location of LM
 Left lobe 46 (30.7.4%)
  S1 9 (19.6%)
  S2 6 (13.0%)
  S3 8 (17.4%)
  S4 24 (52.2%)
   S4a 12 (50.0%)
   S4b 4 (16.7%)
   Unknown 8 (33.3%)
 Right lobe 75 (50.0%)
  S5 13 (17.3%)
  S6 14 (18.7%)
  S7 27 (36.0%)
  S8 21 (28.0%)
 Overlap 26 (17.3%)
  Border S1/S8 1 (3.8%)
  Border S2/S3 6 (23.1%)
  Border S2/S4a 1 (3.8%)
  Border S4a/S4b 2 (7.7%)
  Border S4a/S8 6 (23.1%)
  Border S5/S6 2 (7.7%)
  Border S5/S8 1 (3.8%)
  Border S6/S7 2 (7.7%)
  Border S7/8 5 (19.2%)
 Unknown 3 (2.0%)
Controlled primary
 Yes 103 (89.6%)
 No 12 (10.4%)
LM diagnosis
 Synchronous 35 (23.3%)
 Metachronous 115 (76.7%)
Metastases in other sites
 Yes 58 (50.4%)
 No 57 (49.6%)
Systemic therapy within four weeks before/after RT
 Yes 38 (33.0%)
 No 77 (67.0%)
FU-time (median, range) [months] 11.4 (0–123.3)
  1. LM = liver metastasis; SBRT = stereotactic body radiation therapy; AEG = adenocarcinoma of esophagogastric junction; NSCLC = non-small-cell-lung-cancer; KPS = Karnofsky Performing Score; FU = follow-up; synchronous ≤3 months after initial primary diagnosis; metachronous > 3 months after initial primary diagnosis